The assessment and impact of sarcopenia in lung cancer: A systematic literature review

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Collins, Jemima ^a   Noble, Simon ^a   Chester, John ^a   Coles, Bernadette ^b   Byrne, Anthony ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Velindre NHS Trust   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ARTICLE; BODY MASS; CACHEXIA; DIET SUPPLEMENTATION; FUNCTIONAL STATUS; HUMAN; LUNG CANCER; MUSCLE FUNCTION; MUSCLE MASS; OVERALL SURVIVAL; SARCOPENIA; SECONDARY HEALTH CARE; SYSTEMATIC REVIEW; COMPLICATION; LUNG TUMOR;

CACHEXIA; HUMANS; LUNG NEOPLASMS; SARCOPENIA;

EID: 84892843096     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003697     Document Type: Article

References (91)

1. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629-35.
2. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6.
3. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 2012;31:74-7.
4. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 2012;7:e37563.
5. Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012;107:931-6.
6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 2010;39:412-23.
7. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889-96. (Pubitemid 34496687)
8. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755-63. (Pubitemid 28183275)
9. Landi F, Liperoti R, Fusco D, et al. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc 2012;13:121-6.
10. Cherin P, Voronska E, Fraoucene N, et al. Prevalence of sarcopenia among healthy ambulatory subjects: the sarcopenia begins from 45 years. Aging Clin Exp Res 2013. 17 Oct 2013. Epub ahead of print.
11. Veasey-Rodrigues H, Parsons HA, Janku F, et al. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle 2013;4:259-65.
12. Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013;100:1523-30.
13. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
14. Janssen I, Baumgartner RN, Ross R, et al. Skeletal muscle cut points associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004;159:413-21. (Pubitemid 38200776)
15. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol Ser A Biol Sci Med Sci 2006;61:1059-64. (Pubitemid 44727214)
16. Kendler DL, Borges JL, Fielding RA, et al. The official positions of the International Society for Clinical Densitometry: indications of use and reporting of DXA for body composition. J Clin Densitom 2013;16:496-507.
17. Trutschnigg B, Kilgour RD, Reinglas J, et al. Precision and reliability of strength (Jamar vs. Biodex handgrip) and body composition (dual-energy X-ray absorptiometry vs. bioimpedance analysis) measurements in advanced cancer patients. Appl Physiol Nutr Metab 2008;33:1232-9.
18. Landi F, Russo A, Liperoti R, et al. Mid arm muscle circumference, physical performance and mortality: results from the aging and longevity study in the Sirente geographic area (ilSIRENTE study). Clin Nutr 2010;29:441-7.
19. Freiberger E, de Vreede P, Schoene D, et al. Performance-based physical function in older community-dwelling persons: a systematic review of instruments. Age Ageing 2012;41:712-21.
20. Greendale GA, DeAmicis TA, Bucur A, et al. A prospective study of the effect of fracture on measured physical performance: results from the MacArthur Study-MAC. J Am Geriatr Soc 2000;48: 546-9. (Pubitemid 30263107)
21. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
22. Rachet B, Woods LM, Mitry E, et al. Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 2008;99(Suppl 1): S2-10.
23. Vinod SK, Sidhom MA, Gabriel GS, et al. Why do some lung cancer patients receive no anticancer treatment? J Thorac Oncol 2010;5:1025-32.
24. Pemberton L, Sumra P, Tetlow C, et al. Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice? Lung Cancer 2013;79:S36.
25. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-7S.
26. Villasenor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 2012;6:398-406.
27. Jagoe RT, Goodship TH, Gibson GJ. Nutritional status of patients undergoing lung cancer operations. Ann Thorac Surg 2001;71:929-35. (Pubitemid 32210404)
28. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebocontrolled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7. (Pubitemid 46638896)
29. Harvie MN, Campbell IT, Thatcher N, et al. Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J Hum Nutr Diet 2003;16:323-6. (Pubitemid 37304380)
30. Sanchez-Lara K, Turcott JG, Juarez E, et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer 2012;64:526-34.
31. Granger CL, McDonald CF, Parry SM, et al. Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties. BMC Cancer 2013;13:135.
32. Blum D, Omlin A, Baracos VE, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 2011;80:114-44.
33. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998;2:74-8. (Pubitemid 28222429)
34. Lindsey AM, Piper BF. Anorexia and weight loss: indicators of cachexia in small cell lung cancer. Nutr Cancer 1985;7:65-76. (Pubitemid 16238110)
35. Wolf RF, Pearlstone DB, Newman E, et al. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg 1992;216:280-90.
36. Gioulbasanis I, Baracos VE, Giannousi Z, et al. Baseline nutritional evaluation in metastatic lung cancer patients: mini nutritional assessment versus weight loss history. Ann Oncol 2011;22:835-41.
37. Jamieson NB, Brown DJ, Michael Wallace A, et al. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine 2004;27:90-2. (Pubitemid 38881531)
38. Melville S, McNurlan MA, Calder AG, et al. Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res 1990;50:1125-31. (Pubitemid 20083998)
39. Richards EW, Long CL, Nelson KM, et al. Protein turnover in advanced lung cancer patients. Metabolism 1993;42:291-6. (Pubitemid 23073344)
40. Staal-van den Brekel AJ, Schols AM, Dentener MA, et al. Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax 1997;52:338-41. (Pubitemid 27204895)
41. Staal-van den Brekel AJ, Schols AM, ten Velde GP, et al. Analysis of the energy balance in lung cancer patients. Cancer Res 1994;54:6430-3.
42. van der Meij BS, Schoonbeek CP, Smit EF, et al. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr 2013;109:2231-9.
43. Ovesen L, Hannibal J, Mortensen EL. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 1993;19:159-67. (Pubitemid 23131433)
44. Richards EW, Long CL, Nelson KM, et al. Glucose metabolism in advanced lung cancer patients. Nutrition 1992;8:245-51.
45. Simons JP, Schols AM, Westerterp KR, et al. The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am J Clin Nutr 1995;61:741-5.
46. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010;10:50.
47. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-9.
48. Meek CL, Wallace AM, Forrest LM, et al. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 2010;29:206-9.
49. Toso S, Piccoli A, Gusella M, et al. Altered tissue electric properties in lung cancer patients as detected by bioelectric impedance vector analysis. Nutrition 2000;16:120-4. (Pubitemid 30103713)
50. Agteresch HJ, Rietveld T, Kerkhofs LG, et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002;20:371-8. (Pubitemid 34072518)
51. Dagnelie PC, Agteresch HJ. Promising effects of adenosine triphosphate infusion on nutritional status and quality of life in advanced non-small-cell lung cancer: a randomized clinical trial. Drug Dev Res 2003;59:146-51. (Pubitemid 36682452)
52. Vigano A, Trutschnigg B, Kilgour RD, et al. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. Clin Cancer Res 2009;15:2442-7.
53. Kilgour RD, Vigano A, Trutschnigg B, et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010;1:177-85.
54. Tozer RG, Tai P, Falconer W, et al. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid Redox Signal 2008;10:395-402.
55. Op den Kamp CM, Langen RC, Minnaard R, et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 2012;76:112-17.
56. Peddle-McIntyre CJ, Bell G, Fenton D, et al. Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors. Lung Cancer 2012;75:126-32.
57. McMillan DC, Watson WS, O'Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39:210-13. (Pubitemid 33694037)
58. Crown AL, Cottle K, Lightman SL, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol 2002;56:723-33. (Pubitemid 34785903)
59. Jagoe RT, Redfern CP, Roberts RG, et al. Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitinproteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin Sci 2002;102:353-61. (Pubitemid 34214399)
60. Wieland BM, Stewart GD, Skipworth RJ, et al. Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res 2007;13:4984-92. (Pubitemid 47502062)
61. Martinez-Hernandez PL, Hernanz-Macias A, Gomez-Candela C, et al. Serum interleukin-15 levels in cancer patients with cachexia. Oncol Rep 2012;28:1443-52.
62. Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013;98:738-48.
63. Harvie MN, Howell A, Thatcher N, et al. Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy-a longitudinal study. Br J Cancer 2005;92:673-80. (Pubitemid 40460603)
64. Bovio G, Bettaglio R, Bonetti G, et al. Evaluation of nutritional status and dietary intake in patients with advanced cancer on palliative care. Minerva Gastroenterol Dietol 2008;54:243-50.
65. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539-47.
66. Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013;98:1012-19.
67. Hansell DT, Davies JWL, Burns HJG. The relationship between resting energy expenditure and weight loss in benign and malignant disease. Ann Surg 1986;203:240-5. (Pubitemid 16011285)
68. Fredix EWHM, Soeters PB, Wouters EFM, et al. Energy balance in relation to cancer cachexia. Clin Nutr 1990;9:319-24.
69. Staal-van den Brekel AJ, Schols AM, Dentener MA, et al. The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer 1997;76:1630-5. (Pubitemid 27520593)
70. Simons JP, Schols AM, Campfield LA, et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci 1997;93:273-7. (Pubitemid 27387066)
71. Simons JP, Schols AM, Buurman WA, et al. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci 1999;97:215-23. (Pubitemid 29396627)
72. Scott HR, McMillan DC, Watson WS, et al. Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer. Lung Cancer 2001;32:307-12. (Pubitemid 32487691)
73. Jatoi A, Daly BD, Hughes VA, et al. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001;72:348-51. (Pubitemid 32727125)
74. Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 2003;11:652-9. (Pubitemid 37243596)
75. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy-a pilot study. Support Care Cancer 2005;13:270-4. (Pubitemid 40576515)
76. Murphy RA, Mourtzakis M, Chu QS, et al. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010;140:1602-6.
77. Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011;117:1775-82.
78. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012;31:765-73.
79. Beijer S, Hupperets PS, van den Borne BE, et al. Effect of adenosine 50-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs 2009;20:625-33.
80. Khal J, Hine AV, Fearon KC, et al. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005;37:2196-206. (Pubitemid 41206831)
81. Wang Z, Heshka S, Gallagher D, et al. Resting energy expenditure-fat-free mass relationship: new insights provided by body composition modeling. Am J Physiol Endocrinol Metab 2000;279:E539-45.
82. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013;4:95-109.
83. Murphy RA, Yeung E, Mazurak VC, et al. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011;105:1469-73.
84. McClellan R. Exercise programs for patients with cancer improve physical functioning and quality of life. J Physiother 2013;59:57.
85. Boxer RS, Kenny AM, Dowsett R, et al. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 2005;8:207-12. (Pubitemid 43068314)
86. Argiles JM, Busquets S, Felipe A, et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2005;37:1084-104. (Pubitemid 40311748)
87. Sorensen JB, Klee M, Palshof T, et al. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993;67:773-5. (Pubitemid 23101557)
88. Montoya M, Fossella F, Palmer JL, et al. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med 2006;9:309-16.
89. May CH, Lester JF, Lee S. Performance status discordance and why it matters. Lung Cancer 2012;75(S1):S1-72.
90. Sonpavde G, Vogelzang NJ, Galsky MD, et al. Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. Am J Clin Oncol 2012;35:163-6.
91. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.